checkAd

     298  0 Kommentare Game Changing Tuberculosis Assay Validated for Illumina's MiSeq Platform

    Next Generation Sequencing (NGS) Kit to Improve Speed and Accuracy of M. Tuberculosis (MTB) Drug Sensitivity Testing (DST) at a Fraction of the Current Cost of Sequencing

    BETHESDA, Maryland, Sept. 24, 2018 /PRNewswire/ -- Longhorn Vaccines and Diagnostics LLC (LHNVD), a private pre-analytical systems and molecular solutions company, is pleased to announce the validation of its newest technology, PrimeSeqMDR, across a wide range of well characterized clinical strains of MTB from the Ukraine and South Africa.  PrimeSeqMDR is a proprietary reagent set that allows users to conduct targeted gene sequencing for up to five genes per sample in less than 24 hours.  The development of PrimeSeqMDR was made possible by LHNVD's revolutionary FDA cleared sample collection system, PrimeStore Molecular Transport Medium (PS-MTM), which allows biological samples to be shipped and processed without need for special containment.

    As the United Nations opens a high level meeting this week to seek an urgent global response to end TB, embracing new molecular diagnostic and sequencing products and technologies will be crucial.  With more than 10 million people falling sick with TB globally every year and more than four million of these being missed (StopTB Partnership), every aspect from sample collection to diagnosis, drug sensitivity analysis to treatment regimens, needs to be optimized and supported if the world is truly to end the MTB epidemic by 2030.

    Pyrazinamide (PZA) is an important component of current, and newly embraced drug regimens for multi-drug resistant tuberculosis (MDR-TB).  PZA resistance can occur at multiple points along the pncA gene.   MTB can be resistant to PZA alone or resistant to PZA and other standard MTB drugs.  Direct testing of PZA sensitivity is therefore crucial however it is very difficult to impossible by most methods other than gene sequencing.  The pncA gene target is the cornerstone of the PrimeSeqMDR kit.  The additional gene targets can/will be selected based on current and future drug regimens.  Regionally specific kits can also be manufactured to target circulating strains of concern in different parts of the world.

    Seite 1 von 2


    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Game Changing Tuberculosis Assay Validated for Illumina's MiSeq Platform Next Generation Sequencing (NGS) Kit to Improve Speed and Accuracy of M. Tuberculosis (MTB) Drug Sensitivity Testing (DST) at a Fraction of the Current Cost of Sequencing BETHESDA, Maryland, Sept. 24, 2018 /PRNewswire/ - Longhorn Vaccines and …